Protagonist Therapeutics reported a significant increase in license and collaboration revenue to $544.3 million for the nine months ended September 30, 2026, resulting in a net income of $386.6 million compared to a net loss in the prior year. The company's cash position strengthened considerably, with total assets reaching $1.15 billion as of the end of the third quarter.
Protagonist Therapeutics reported Q3 2026 financial results, highlighted by the FDA approval of MIMRYLO (rusfertide) for polycythemia vera, which triggered $275 million in payments from partner Takeda. The company ended the quarter with $834.6 million in cash and announced a $300 million share repurchase program.
Term
Q3 2026
“The third quarter was a defining period for Protagonist, with FDA approval of MIMRYLO, our second approval this year for a first-in-class peptide drug, and the continued strong commercial launch of ICOTYDE under our collaboration with Johnson & Johnson.”
Dinesh V. Patel, PhD, President and Chief Executive Officer
“The partnerships are fueling an accelerating revenue engine, which provides the flexibility to fund the next generation of wholly owned programs emerging from our platform, and to return meaningful capital to shareholders through a share repurchase program.”
Dinesh V. Patel, PhD, President and Chief Executive Officer